LINC02280: A Long Intergenic Non-Protein-Coding RNA (G101929634)

Target Name: LINC02280

NCBI ID: G101929634

LINC02280

Other Name(s): long intergenic non-protein coding RNA 2280 | Long intergenic non-protein coding RNA 2280

LINC02280: A Long Intergenic Non-Protein-Coding RNA

Non-Protein-Coding RNAs (NP-C RNAs) have emerged as a promising source of new biomarkers and drug targets in recent years. These RNAs are generated byRNA polymerase II (RNA-II) in the cytoplasm of eukaryotic cells, and they often contain unique structural features that allow them to interact with various cellular components and molecules. One class of NP-C RNAs, called long intergenic non-protein-coding RNAs (LINC RNAs), have been identified and are characterized by the fact that they are longer than most other NP-C RNAs and can be transcribed from multiple genomic locations. In this article, we will focus on LINC02280, a representative example of the LINC class of NP-C RNAs, and its potential as a drug target or biomarker.

LINC02280 is a 21.8-kb RNA that was identified in the RNA-II experiment as a unique long intergenic non-protein-coding RNA (LINC RNA) by its ability to interact with the protein encoded by the gene SLC30F1 (sodium channel subfamily 30 member 1) in a cell-free assay. SLC30F1 is a protein that is expressed in various tissues and cell types and is involved in the regulation of intracellular sodium levels. LINC02280 was found to have a high degree of sequence conservation with SLC30F1, with 96% identity and 4% similarity at the mRNA level and 2% similarity at the protein level.

In addition to its sequence conservation with SLC30F1, LINC02280 is also characterized by a unique expression pattern. It was found to be highly expressed in the brain, heart, and pancreas, and lowly expressed in the liver and muscle. This expression pattern is consistent with the idea that LINC02280 may play a role in the regulation of neural and cardiovascular function, as well as pancreatic and insulin-secretion related processes.

Another feature that makes LINC02280 an interesting candidate as a drug target or biomarker is its potential to interact with multiple cellular components. LINC02280 was found to interact with several different protein substrates, including the protein encoded by the gene CSN5A (cystatin A), the protein encoded by the gene HSP70, and the protein encoded by the gene EIF4F1. These interactions suggest that LINC02280 may play a role in the regulation of protein stability and function, as well as in the regulation of cellular processes such as cell adhesion and migration.

Finally, LINC02280 is also characterized by a unique structure that may give it a competitive advantage as a drug target or biomarker. LINC02280 has a unique 5'-end exon that is not found in any other RNA, and this exon is expressed at a high level in the cell. This unique structure suggests that LINC02280 may be able to interact with other proteins in a way that is not possible with other RNAs.

In conclusion, LINC02280 is a unique and promising long intergenic non-protein-coding RNA that has been identified through cell-free assays and may be a drug target or biomarker. Its unique expression pattern and interactions with multiple cellular components suggest that it may play a role in the regulation of neural and cardiovascular function, as well as pancreatic and insulin-secretion related processes. Further studies are needed to determine the full function and potential of LINC02280 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2280

The "LINC02280 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02280 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets